Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

Rhea-AI Summary

Cybin, a biopharmaceutical company advancing psychedelics for therapeutic use, announces participation in key investor events in November 2022. CEO Doug Drysdale will present at the Jefferies London Healthcare Conference on November 15 at 8:00 a.m. GMT and engage in investor meetings. He will also join the Pinsent Masons Psychedelics Panel on November 16 at 5:00 p.m. GMT. Additionally, Drysdale will take part in the PSYCH Investor Event on November 17 for a fireside chat at 5:00 p.m. GMT. Archived webcasts will be available on Cybin’s investor website.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics^®, is pleased to announce its participation in the following upcoming investor events:

Jefferies London Healthcare Conference, November 15-17, 2022

• Doug Drysdale, Cybin’s Chief Executive Officer, will present on November 15, 2022 at 8:00 a.m. GMT and host investor meetings. To listen to the presentation, please click here to register and access the webcast.

Pinsent Masons Psychedelics Panel, November 16, 2022, in London, UK

• Mr. Drysdale will participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at 5:00 p.m. GMT. To listen to the panel, please click here to register and access the webcast.

PSYCH Investor Event: Emerging Innovations in Psychedelic Healthcare, November 17, 2022, in London, UK

• Mr. Drysdale will participate in a live fireside chat at 5:00 p.m. GMT with other industry thought leaders.

The live and archived webcasts will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005422/en/

Investor & Media Inquiries for Cybin:

Leah Gibson

Vice President, Investor Relations & Strategic Communications

Cybin Inc.

irteam@cybin.com – or – media@cybin.com

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

Source: Cybin Inc.

FAQ

What investor events is Cybin participating in November 2022?

Cybin will participate in the Jefferies London Healthcare Conference from November 15-17, the Pinsent Masons Psychedelics Panel on November 16, and the PSYCH Investor Event on November 17.

When will Cybin's CEO present at the Jefferies London Healthcare Conference?

Doug Drysdale, Cybin's CEO, will present on November 15, 2022, at 8:00 a.m. GMT.

What topics will be discussed at the Pinsent Masons Psychedelics Panel?

The panel will focus on the "Psychedelics Landscape – What can we expect?" and is scheduled for November 16, 2022, at 5:00 p.m. GMT.

What is the PSYCH Investor Event about?

The PSYCH Investor Event will feature a fireside chat with Cybin's CEO Doug Drysdale on November 17, 2022, at 5:00 p.m. GMT.

Where can I find the archived webcasts for Cybin's investor events?

Archived webcasts will be available on Cybin's investor relations website under the Events & Presentations section.